Scholarlink

Objectives <p>Lefamulin is a novel pleuromutilin antibiotic used for the treatment of community-acquired pneumonia (CAP). This study aimed to evaluate the in vitro antimicrobial activity of lefamulin against clinical isolates obtained from China.</p> Methods <p>1,052 non-duplicate isolates included the following isolates: <i>Streptococcus pneumoniae</i> (<i>n</i> = 529), <i>Staphylococcus aureus</i> (<i>n</i> = 306), <i>Haemophilus influenzae</i> (<i>n</i> = 121), <i>Moraxella catarrhalis</i> (<i>n</i> = 81), and <i>Mycoplasma pneumoniae</i> (<i>n</i> = 15), were collected from 70 hospitals participating in the China Antimicrobial Surveillance Network (CHINET) between October 1, 2020, and November 30, 2022. Minimum inhibitory concentrations were determined using the broth microdilution method in accordance with the standards set by the Clinical and Laboratory Standards Institute. Results: In vitro, <i>S. pneumoniae</i> exhibited 100% sensitivity to lefamulin, with MIC<sub>90</sub> values of 0.125&#xa0;µg/mL for penicillin-susceptible strains, 0.25&#xa0;µg/mL for penicillin-intermediate strains, and 0.125&#xa0;µg/mL for penicillin-resistant strains. Lefamulin remained effective against <i>S. pneumoniae</i> strains resistant to penicillin, erythromycin, and azithromycin. The susceptibility rate of <i>S. aureus</i> to lefamulin was 97.7%, with methicillin-sensitive <i>S. aureus</i> showing 98.4% sensitivity and methicillin-resistant <i>S. aureus</i> showing 96.6% sensitivity. Both strains had MIC<sub>90</sub> values of 0.125&#xa0;µg/mL. <i>H. influenzae</i> and <i>M. catarrhalis</i> demonstrated 100% sensitivity to lefamulin. The MIC of lefamulin against <i>M. pneumoniae</i> was ≤ 0.03&#xa0;µg/mL.</p> Conclusions <p>Lefamulin exhibited potent in vitro activity against prevalent and drug-resistant pathogens associated with CAP in China.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antimicrobial activity of lefamulin against pathogens most commonly causing community-acquired pneumonia: results from the China antimicrobial surveillance network in 2020–2022

  • 期刊论文

  • 发表日期：

    2025年5月28日

查看全文
  • Li Ding,
  • Siquan Shen,
  • Renru Han,
  • Dandan Yin,
  • Yang Yang,
  • Shi Wu,
  • Demei Zhu,
  • Yan Guo,
  • Fupin Hu

摘要

Objectives

Lefamulin is a novel pleuromutilin antibiotic used for the treatment of community-acquired pneumonia (CAP). This study aimed to evaluate the in vitro antimicrobial activity of lefamulin against clinical isolates obtained from China.

Methods

1,052 non-duplicate isolates included the following isolates: Streptococcus pneumoniae (n = 529), Staphylococcus aureus (n = 306), Haemophilus influenzae (n = 121), Moraxella catarrhalis (n = 81), and Mycoplasma pneumoniae (n = 15), were collected from 70 hospitals participating in the China Antimicrobial Surveillance Network (CHINET) between October 1, 2020, and November 30, 2022. Minimum inhibitory concentrations were determined using the broth microdilution method in accordance with the standards set by the Clinical and Laboratory Standards Institute. Results: In vitro, S. pneumoniae exhibited 100% sensitivity to lefamulin, with MIC90 values of 0.125 µg/mL for penicillin-susceptible strains, 0.25 µg/mL for penicillin-intermediate strains, and 0.125 µg/mL for penicillin-resistant strains. Lefamulin remained effective against S. pneumoniae strains resistant to penicillin, erythromycin, and azithromycin. The susceptibility rate of S. aureus to lefamulin was 97.7%, with methicillin-sensitive S. aureus showing 98.4% sensitivity and methicillin-resistant S. aureus showing 96.6% sensitivity. Both strains had MIC90 values of 0.125 µg/mL. H. influenzae and M. catarrhalis demonstrated 100% sensitivity to lefamulin. The MIC of lefamulin against M. pneumoniae was ≤ 0.03 µg/mL.

Conclusions

Lefamulin exhibited potent in vitro activity against prevalent and drug-resistant pathogens associated with CAP in China.